PriceTargets.com logo

Nautilus Biotechnology - NAUT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $4.50
  • Forecasted Upside: 92.31%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.34 As of 11/20/2024 01:00 AM ET
▲ +0.1 (4.46%)

This chart shows the closing price for NAUT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nautilus Biotechnology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NAUT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NAUT

Analyst Price Target is $4.50
▲ +92.31% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Nautilus Biotechnology in the last 3 months. The average price target is $4.50, with a high forecast of $6.00 and a low forecast of $3.00. The average price target represents a 92.31% upside from the last price of $2.34.

This chart shows the closing price for NAUT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 contributing investment analysts is to moderate buy stock in Nautilus Biotechnology. This rating has held steady since July 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/27/2024GuggenheimInitiated CoverageBuy$6.00
6/3/2024Jefferies Financial GroupInitiated CoverageBuy ➝ Hold$5.00 ➝ $3.00
8/3/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$6.00
8/3/2022Morgan StanleyLower TargetEqual Weight$8.00 ➝ $6.00
8/3/2022The Goldman Sachs GroupLower TargetNeutral$4.00 ➝ $2.00
7/14/2022The Goldman Sachs GroupLower TargetNeutral$5.00 ➝ $4.00
4/13/2022The Goldman Sachs GroupLower TargetNeutral$9.00 ➝ $5.00
1/6/2022Morgan StanleyInitiated CoverageEqual Weight$8.00
11/2/2021CowenInitiated CoverageOutperform
8/4/2021The Goldman Sachs GroupInitiated CoverageNeutral$10.00
7/13/2021Jefferies Financial GroupInitiated CoverageBuy$13.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

-0.05 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 0 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 0 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Nautilus Biotechnology logo
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $2.34
Low: $2.21
High: $2.35

50 Day Range

MA: $2.72
Low: $2.24
High: $3.08

52 Week Range

Now: $2.34
Low: $2.19
High: $3.45

Volume

68,322 shs

Average Volume

78,789 shs

Market Capitalization

$293.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23

Frequently Asked Questions

What sell-side analysts currently cover shares of Nautilus Biotechnology?

The following equities research analysts have issued stock ratings on Nautilus Biotechnology in the last year: Guggenheim, and Jefferies Financial Group Inc..
View the latest analyst ratings for NAUT.

What is the current price target for Nautilus Biotechnology?

0 Wall Street analysts have set twelve-month price targets for Nautilus Biotechnology in the last year. Their average twelve-month price target is $4.50, suggesting a possible upside of 92.3%. Guggenheim has the highest price target set, predicting NAUT will reach $6.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $3.00 for Nautilus Biotechnology in the next year.
View the latest price targets for NAUT.

What is the current consensus analyst rating for Nautilus Biotechnology?

Nautilus Biotechnology currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for NAUT.

What other companies compete with Nautilus Biotechnology?

Other companies that are similar to Nautilus Biotechnology include Tenaya Therapeutics, BioAtla, Affimed, ORIC Pharmaceuticals and Transcat. Learn More about companies similar to Nautilus Biotechnology.

How do I contact Nautilus Biotechnology's investor relations team?

Nautilus Biotechnology's physical mailing address is 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003. The company's listed phone number is 206-333-2001 and its investor relations email address is [email protected]. The official website for Nautilus Biotechnology is www.nautilus.bio. Learn More about contacing Nautilus Biotechnology investor relations.